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Background: Research has identified associations between serum 25(OH)D and a range of clinical 70 
outcomes in the chronic kidney disease and wider populations.  The study aim was to investigate  71 
vitamin D deficiency/insufficiency in dialysis patients and the relationship with vitamin D intake 72 
and sun exposure. 73 
Methodology: A cross-sectional study was used.  Participants included 30 peritoneal dialysis 74 
(43.3% male; 56.87+16.16 y) and 26 haemodialysis patients (80.8% male; 63.58+15.09 y) 75 
attending a department of renal medicine.   76 
Explanatory variables were usual vitamin D intake from diet/supplements (IU/d) and sun exposure 77 
(minutes/day)   Vitamin D Intake, sun exposure and ethnic background were assessed  by 78 
questionnaire.  Weight, malnutrition status and routine biochemistry were also assessed.  Data was 79 
collected during usual department visits.  The main outcome measure was serum 25(OH)D 80 
(nmol/L). 81 
Results Prevalence of inadequate/insufficient vitamin D intake differed between dialysis modality 82 
with 31% and 43% insufficient (<50nmol/L) and 4% and 33% deficient (<25nmol/L) in HD and PD 83 
patients respectively (P<0.001). In HD patients, there was a correlation between diet and 84 
supplemental vitamin D intake and 25(OH)D (ρ=0.84, P<0.001) and average sun exposure and 85 
25(OH)D (ρ=0.50, P<0.02).  There were no associations in PD patients. Results remained 86 
significant for vitamin D intake following multiple regression, adjusting for age, gender and sun 87 
exposure.    88 
Principal Conclusions Results highlight a strong association between vitamin D intake and 89 
25(OH)D in HD but not PD patients, with implications for replacement recommendations. Findings 90 
indicate that even in a sunny climate many dialysis patients are vitamin D deficient highlighting the 91 
need for exploration of determinants and consequences. 92 
 93 
 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
INTRODUCTION  103 
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In chronic kidney disease (CKD) patients, observational research has identified an association 104 
between serum 25(OH)D and a range of clinical outcomes including mortality, albuminuria, 105 
cardiovascular events, coronary artery calcification, bone fractures and CKD progression (Nigwekar 106 
et al., 2012).  Maintaining adequate levels of vitamin D in this population reflects guideline 107 
recommendations for monitoring and treating low serum 25(OH)D in CKD patients (Kidney 108 
Disease Improving Global Outcomes Work Group, 2009, Kidney Disease Outcomes Quality 109 
Initiative, 2003) and could confer health benefits. 110 
 111 
While optimal serum 25(OH)D concentrations have not been established in either the general or 112 
CKD populations, there is consensus that levels of 25(OH)D below 25 nmol/L indicate “deficiency” 113 
and below 50 nmol/L indicate “insufficiency” (Kimlin et al., 2007). However alternative minimum 114 
targets of 75 nmol/L or 100 nmol/L have been suggested (Holick, 2005), resulting in a lack of 115 
consistency across research in dialysis populations.    Irrespective of the targets selected, multiple 116 
studies have shown notable proportions of participants with suboptimal 25(OH)D concentrations.  117 
For example levels below 37 nmol/L have been reported in 19.5 to 92% of peritoneal dialysis (PD) 118 
(Bindal and Taskapan, 2011, Elder, 2007, Nolph et al., 1984, Taskapan et al., 2006, Wang et al., 119 
2008) and 13 to 86% of haemodialysis (HD) patients (Anand et al., 2011, Barreto et al., 2009, 120 
Boudville et al., 2010, Chang et al., 2012, Coen et al., 2005, Del Valle et al., 2007, Elder, 2007, 121 
Gonzalez et al., 2004, Gracia-Iguacel et al., 2010, Jean et al., 2008, Lee et al., 2012, Milinkovic et 122 
al., 2009, Mucsi et al., 2005, Pecovnik-Balon et al., 2009, Saab et al., 2007, Tolouian et al., 2010).   123 
 124 
The substantial variation in 25(OH)D concentration between individuals and groups could be due to 125 
factors including latitude, skin pigmentation, vitamin D intake from food and supplements and sun 126 
protection culture (Holick, 2005). In addition, there is a range of factors specific to dialysis patients 127 
that may further explain the aetiology of vitamin D deficiency/insufficiency in  this group, in 128 
particular but not limited to: lower dietary intake (Korkor et al., 2009) possibly due to dietary 129 
restrictions and decreased appetite; limited mobility and time outdoors (Clayton and Singer, 2009, 130 
Korkor et al., 2009); reduced synthesis of cholecalciferol in the skin due to reduced glomerular 131 
filtration rate (Michaud et al., 2010); and losses in the peritoneal fluid (Sahin et al., 2009). 132 
However, the evidence discriminating between dietary and sun exposure sources of vitamin D is 133 
scant.  One previous study investigated vitamin D intake in stages 3 to 5 CKD, but only 20% of the 134 
participants were stage 5 (Holden et al., 2010). Four studies investigated vitamin D intake from diet 135 
and/or supplements in kidney transplant recipients (Ewers et al., 2008, Lynch et al., 2007, Heaf et 136 
al., 2004), or stages 3 and 4 CKD patients (Sekkarie, 2006), all of whom have dietary restrictions 137 
that differ from dialysis patients (Ash et al., 2006).  Only two studies have investigated sun 138 
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exposure in CKD patients – within kidney transplant recipients (Ewers et al., 2008) and dialysis 139 
patients (Del Valle et al., 2007).   140 
 141 
While cross-sectional studies have found that low serum 25(OH)D  is an issue in dialysis patients, 142 
Australian studies conducted in Canberra (Clayton and Singer, 2009), Sydney (Elder, 2007) and 143 
Perth (Boudville et al., 2010) provide little evidence for patients in subtropical climates such as 144 
Brisbane.  One Brisbane study  of stage 1 to 5 pre-dialysis patients found 10% and 42% of patients 145 
with 25(OH)D levels below 37.5 nmol/L and between 37.5 to 75 nmol/L, respectively (Petchey et 146 
al., 2012).  Studies of the general population in Brisbane report 25(OH)D deficiency and 147 
insufficiency in 10% and 31% respectively (Kimlin et al., 2007).  None of these studies, however, 148 
distinguished contributions from sun exposure behaviours, usual dietary vitamin D intake and 149 
vitamin D supplements.  The aim of this study therefore was to investigate the serum 25(OH)D 150 
levels of HD and PD patients attending a large tertiary hospital in Brisbane and to examine the 151 
contribution of sun exposure, vitamin D intake from food and supplements towards serum 25(OH)D 152 
levels.  This work will provide further data on the prevalence of vitamin D deficiency/ insufficiency 153 
in dialysis patients and the relationship with dietary and sun exposure behaviours and inform the 154 
development and implementation of intervention strategies. 155 
 156 
METHODS 157 
Study design and participants 158 
This cross-sectional study recruited patients within the Department of Renal Medicine at The Royal 159 
Brisbane and Women’s Hospital (RBWH). 160 
Participants were male and female patients aged over 18 years undergoing PD or HD. Exclusion 161 
criteria were inability to communicate in English or lack of cognitive capacity to consent or 162 
participate. Potential participants were identified through renal unit records and screened for 163 
eligibility by examination of medical records and discussion with nursing staff.   All eligible PD 164 
and HD patients were mailed an information pack indicating they would be invited to participate 165 
during their clinic visit in the following week. Data were collected from PD patients during their 166 
routine clinic visit across August to December 2009 inclusive and from HD patients during their 167 
HD treatments over two weeks in December 2010.  Data were collected for two student research 168 
projects conducted one year apart.   169 
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PD patients were contacted by telephone. If consent was given, data were collected around the time 170 
of their next clinic appointment. HD patients were approached during their regular dialysis 171 
treatment and data collected at that time. Informed consent was obtained for 56 participants, 172 
including 30 of 78 (37%) of the PD program and 26 of 40 (65%) of the HD program.  Of these, one 173 
PD and seven HD participants did not complete the dietary vitamin D intake and sun exposure 174 
section of the questionnaire.  The RBWH Research Ethics Committee and Queensland University of 175 
Technology (QUT) Human Research Ethics Committee approved the study protocol. 176 
Variables and data sources/measurement 177 
AusSun General Health and Sun Skin and Diet Questionnaires 178 
The AusSun General Health and Sun Skin and Diet Questionnaires (AusSun) were modified to 179 
include only the sections on ethnic origin, sun exposure and dietary and supplemental vitamin D 180 
intake.  Sections on education, occupation, smoking, alcohol, general health were excluded as they 181 
were not deemed relevant to this study.  Information on medication was able to be extracted from 182 
medical charts if needed.  Data were collected by a dietitian or final year dietetics student who had 183 
completed all clinical placements required by the university.   184 
Investigators recorded the use of inactive vitamin D supplements (cholecalciferol), including brand 185 
name, dose and frequency of use over the previous month. Specific vitamin D content of 186 
supplements was sourced from MIMS online, the AUSNUT 2007 supplement composition database  187 
(Australian Government., 2007) or by contacting pharmaceutical companies. Dietary vitamin D 188 
intake was assessed using the targeted food frequency questionnaire (FFQ) including foods and 189 
beverages with naturally occurring or fortified vitamin D (AusSun). Participants self-reported their 190 
usual intake compared to a standard serve and average frequency of consumption over the previous 191 
month. Food models and standard utensils were used to improve estimation accuracy. The vitamin 192 
D content of all items was sourced from published Australian values from the AUSNUT 2007 193 
nutrient composition database (Australian Government., 2007). Vitamin D intake was analysed as a 194 
continuous variable and also dichotomized according to whether participant’s intake was above the 195 
Nutrient Reference Value for their age and gender (Commonwealth of Australia., 2006). 196 
Participants estimated time spent outdoors for each hour between 5am and 7pm each day over the 197 
previous month. Available responses were: never, <15 minutes, 15-30 minutes, 30-45 minutes or 198 
45-60 minutes. Data were summed for daily exposure using the lowest, highest and mid-point for 199 
each response and averaged for weekdays, weekends and overall. Time spent outdoors was 200 
analysed as a continuous variable and a dichotomous categorical variable based on whether duration 201 
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was less than or equal to 30 minutes per day versus more than 30 minutes a day.  Summation is a 202 
well-established measure to assess the exposures of individuals by calculating an average of the 203 
large day-to-day variability and has been used in previous studies using questionnaires or activity 204 
logs to estimate exposure  (Kimlin et al., 2007, Parisi et al., 2000).   205 
Serum 25-OHD 206 
Non-fasting blood samples were taken from the participants at the RBWH, centrifuged, and 207 
transported to QUT within two hours of venipuncture then frozen at -80°C. Serum 25(OH)D was 208 
measured on all samples as a single batch using a commercial chemiluminescent immunoassay 209 
(LIAISON_ 25(OH) Vitamin D TOTAL Assay, DiaSorin, Inc., Stillwater, MN). This assay 210 
measures both 25(OH)D2 (ergocalciferol) and 25(OH)D3 (cholecalciferol) (AusSun).  Intra-assay 211 
variability was 3-6% for serum 25(OH)D. Corresponding values for inter-assay variability were 6-212 
9%.  The laboratory undertaking the testing is a participant in the Vitamin D External Quality 213 
Assessment Scheme (DEQAS). 214 
Participant Characteristics 215 
Nutritional status was assessed by the patient-generated subjective global assessment (PG-SGA) 216 
(Detsky et al., 1987) by research staff.  If dietetic staff had conducted a routine PG-SGA within the 217 
same week as data collection a separate PG-SGA was not collected.  Nutritional status categories 218 
were well-nourished (A), moderate or suspected malnutrition (B) or severely malnourished (C).   219 
The most recent dry weight available, assessed by nursing staff, was extracted from patient charts.  220 
Height was self-reported.  Body mass index (BMI) was calculated as body weight divided by 221 
squared height.  BMI ≥ 23 kg/m2 and ≤ 26 kg/m2 was used to reflect optimal nutritional status (Ash 222 
et al., 2006).  The use of a BMI range higher than the 18.5 to 25 kg/m2 recommended for the 223 
healthy population (World Health Organization., 2000) is based upon evidence suggesting a lower 224 
BMI is associated with higher mortality rates in dialysis patients (Salahudeen, 2003). 225 
 226 
Age, dialysis vintage (months since commencement), height, routine biochemistry (phosphate, 227 
potassium, albumin and urea) and blood pressure were obtained from participant charts.  Kt/V 228 
(dialyser clearance of urea multiplied by time over volume of distribution of urea) was used as a 229 
marker of dialysis adequacy. In Australia the target recommended for Kt/V is ≥1.4 to ensure the 230 
delivered dose is above 1.2 for HD patients (Kerr et al., 2005).  For PD the weekly target is ≥ 231 
1.6/week (Johnson et al., 2005).    232 
Data analysis 233 
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Data were analysed in PASW statistics (formerly SPSS) version 19. Patient characteristic data are 234 
expressed as median and range or mean and standard deviation according to normality status. To 235 
address the aim of investigating vitamin D status in PD and HD groups 25(OH)D was analysed as a 236 
continuous and ordinal variable. Cut-points for the categorization of 25(OH)D were ≤  25 nmol/L 237 
for vitamin D deficiency, and between 25 and  50  nmol/L for vitamin D insufficiency based on 238 
Australian recommended position statements for vitamin D and adult bone health (Working Group 239 
of the Australian and New Zealand Bone and Mineral Society et al., 2005).   As minimum targets of 240 
75 nmol/L have also been recommended (Holick, 2005) the percentage of participants above this 241 
level was also calculated.  For comparison between dialysis groups Student unpaired t-tests and 242 
Mann-Whitney U tests were used for normal and non-normal continuous data respectively and 243 
Pearson’s Chi-square tests were used for categorical data.  244 
 245 
Spearman’s rank-order correlations were used to address the aim of investigating associations 246 
between 25(OH)D and vitamin D intake or sun exposure variables .  Multiple regression analyses 247 
were used to investigate the relationship between Vitamin D intake and serum 25(OH)D, 248 
controlling for gender, age and sun exposure in PD and HD groups  Standardized beta coefficients 249 
were used to investigate the contribution of the explanatory variables towards predicting serum 250 
25(OH)D. 251 
RESULTS  252 
Serum 25-hydroxyvitamin D was measured in 30 PD and 26 HD patients.  Of these one PD and 253 
seven HD patients did not complete the questionnaire.  These participants were excluded from the 254 
multiple regression analysis.  Ethnicity and BMI data were not reported in three and four HD 255 
patients respectively.  These participants were not excluded as ethnicity and BMI were not included 256 
in multiple regression analysis.   257 
No significant differences were shown for age, gender, dialysis vintage, Kt/V and BMI at the start 258 
of renal replacement therapy in participants compared to eligible members of the RBWH population 259 
that did not consent to participate and the overall PD and HD population in Australia as identified 260 
by ANZDATA (Australia and New Zealand Dialysis and Transplant Registry, data not shown).  261 
There were also no significant differences between dialysis modalities for age, ethnic background, 262 
dialysis vintage, BMI, serum albumin and serum phosphate between PD and HD (Table 1). A 263 
higher proportion of female patients received PD (17/22) compared to males (13/34).  When 264 
compared to HD, PD patients had lower systolic blood pressure, serum urea and potassium and 265 
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higher Kt/V. Malnutrition (SGA score B or C) was identified in 7.7% of PD and 7.1% of HD 266 
patients.  20.5% of PD and 15% of HD patients were below optimal BMI (BMI<23kg/m2) and 267 
51.3% of PD and 55% of HD patients were above optimal BMI (BMI>26kg/m2).  There were no 268 
significant differences in malnutrition or BMI status between dialysis groups. 269 
There was a significant and substantial difference between PD and HD patients for prevalence of 270 
vitamin D insufficiency/deficiency (Table 2). Using the target of 75 nmol/L 25(OH)D levels were 271 
sufficient in 14.3% (n=8) of patients (n=2 (6.7%) and n=6 (23.1%) for PD and HD respectively).  272 
There was no difference between dialysis groups for dietary, supplemental or total (dietary plus 273 
supplemental) vitamin D intake or sun exposure.  Only average sun exposure data are presented, as 274 
patterns for estimates of maximum and minimum exposure on weekdays and weekends were 275 
similar. Vitamin D intake was below the Nutrient Reference Value for age and gender in 81.6% of 276 
PD and 78.9% of HD patients. 277 
Correlations between serum 25(OH)D and vitamin D intake and sun exposure variables are shown 278 
in table 3. For PD patients there were no significant associations between serum 25(OH)D and any 279 
other variable. In contrast, in HD patients, there were significant and substantial associations 280 
between serum 25(OH)D and: total  vitamin D intake and supplemental intake; sun exposure - 281 
minimum weekday, maximum weekday and maximum weekend. There was a trend for an 282 
association with dietary vitamin D intake alone.  283 
Regression weights for the three control variables (gender, age and sun exposure) did not reach or 284 
approach significance (Table 4) and were particularly small for sun exposure for both HD and PD 285 
groups, indicating sun exposure had little impact upon 25(OH)D levels. The relationship between 286 
total intake and 25(OH)D was very strong for HD patients and can be described as: an increased 287 
intake of 40 IU (1µg) per day corresponded to an increase of 2.5 nmol/L in 25(OH)D concentration. 288 
For PD participants, the relationship was weak and non-significant.  These results were similar 289 
irrespective of the inclusion of control variables. 290 
DISCUSSION 291 
The finding of a significant correlation between vitamin D intake and serum 25(OH)D for HD but 292 
not PD patients has not, to our knowledge, been reported in any other studies.  A possible reason for 293 
the association in HD but not PD patients could be loss of 25(OH)D in the peritoneal dialysate 294 
fluid.  A study which found lower 25(OH)D in PD compared to HD patients also reported 295 
significantly higher 25(OH)D levels in the peritoneal fluid compared to blood (28. vs. 13.00 296 
nmol/L) (Sahin et al., 2009).  There is limited and inconsistent prospective research on the ability of 297 
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supplementation to raise 25(OH)D levels in PD patients.  One study reported that 27 patients given 298 
41 440 IU of ergocalciferol once per week showed increased 25(OH)D levels, but 26 of the patients 299 
remained below 75 nmol/L after four weeks (Bouchard et al., 2008). Another trial of 23 PD patients 300 
used 50 000 IU of ergocalciferol per week and only one patient remained below 75 nmol/L  (Shah 301 
et al., 2005). 302 
Our results showing serum 25(OH)D concentration is higher in patients on HD (53.66 nmol/L) than 303 
PD  (33.2 nmol/L) are supported by two other Australian studies (Clayton and Singer, 2009, Elder, 304 
2007) that demonstrated levels of 77 and 50 nmol/L in HD and 50 and 35 nmol/L in PD patients 305 
respectively.  A study in Turkey also found lower levels in PD compared to HD patients (12.5 and 306 
22.5 nmol/L, respectively) (Sahin et al., 2009).  Possible reasons for differences in PD and HD 307 
patients, apart from loss in peritoneal dialysate, could relate to vitamin D intake and/or sun 308 
exposure behaviours.  However as PD patients have less restrictive dietary recommendations (Ash 309 
et al., 2006) and have greater freedom from dialysis during the daytime these factors do not provide 310 
a rationale for lower 25-hydroxyvitamin D in PD patients.  Possible confounding factors could also 311 
contribute to differences.  Age and gender were both adjusted for in multivariable analysis and 312 
ethnicity did not have a significant effect on results however other characteristics such as education 313 
and living arrangements were not measured.    Our data are similar to other studies in Australia 314 
which have shown serum 25(OH)D <50 nmol/L in 39% of a combined group of PD and HD 315 
patients (Elder, 2007), 49% of HD and 77% of PD (Clayton and Singer, 2009) and 36% of HD 316 
patients (Boudville et al., 2010).  The proportion of patients with 25(OH)D <50 nmol/L varied to a 317 
greater extent across international studies.  US studies reported proportions of 97% (Shah et al., 318 
2005) in PD patients and 54 to 77% (Bhan et al., 2010, Blair et al., 2008, Tolouian et al., 2010) in 319 
HD patients.   In HD patients in Europe prevalence was 28 to 71% in Germany (Drechsler et al., 320 
2010, Krause et al., 2012) Italy (Santoro et al., 2011) and Serbia (Milinkovic et al., 2009).  321 
Compared to findings of 25(OH)D deficiency/insufficiency reported in studies of the general 322 
Brisbane population of 42.5% (Kimlin et al., 2007) and 31% (McGrath et al., 2001), the proportion 323 
of patients was similar in the HD group and higher in the PD group.  Overall, studies have indicated 324 
the occurrence of sub-optimal 25(OH)D concentration is widespread and across a range of latitudes. 325 
Mean dietary intakes of vitamin D were well below the Australian recommendations of 5 to 15 326 
µg/day (200IU-400IU) depending on age (Commonwealth of Australia., 2006). To our knowledge 327 
no other study has assessed vitamin D intake in dialysis patients.  Findings were similar to  research 328 
conducted in kidney transplant patients which reported dietary vitamin D intakes ranging from 120 329 
IU/day (Ewers et al., 2008, Heaf et al., 2004) to 200 IU/day (Lynch et al., 2007)  and were lower 330 
than average reported intakes of 473.2+380 IU/day from diet and supplements combined in stage 3 331 
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to 5 CKD patients (Holden et al., 2010).   While supplements improved the intake of the current 332 
sample above recommended levels, they were only taken by seven (24%) of the PD and four (21%) 333 
of the HD patients and did not significantly increase the median vitamin D intake (Table 2).  Other 334 
studies that have assessed vitamin D supplementation reported usage by 34.3% of stage 3 and 4 335 
CKD patients in the US (Sekkarie, 2006) and 10.2% and 60.8% of kidney transplant recipients in 336 
Ireland (Lynch et al., 2007) and Denmark (Ewers et al., 2008) respectively.  The proportion of 337 
patients with suboptimal 25(OH)D not taking supplements is in contrast to current guidelines 338 
(Kidney Disease Improving Global Outcomes Work Group, 2009, Kidney Disease Outcomes 339 
Quality Initiative, 2003) recommending monitoring of 25(OH)D in dialysis patients and treatment 340 
using inactive vitamin D supplements (Kidney Disease Improving Global Outcomes Work Group, 341 
2009, Kidney Disease Outcomes Quality Initiative, 2003).  342 
Median daily sun exposure of 39 mins PD and 33 mins HD was  above the recommended levels for 343 
persons living in Brisbane (6 -7 mins in summer and 15-19 minutes in winter (Working Group of 344 
the Australian and New Zealand Bone and Mineral Society et al., 2005)). However exposure ranged 345 
from none to 454 mins/day. There is little comparable information about sun exposure and 346 
25(OH)D in CKD patients.  A Danish study reported lower 25(OH)D levels of 45 nmol/L in kidney 347 
transplant recipients reporting sun avoidance compared to  60 nmol/L in the partial or no sun 348 
avoidance group (P<0.05) (Ewers et al., 2008).  Behaviours in transplant recipients may be 349 
influenced by clinical advice on sun protection due to the increased risk of skin cancer with 350 
immunosuppression (Feuerstein and Geller, 2008).  A study in Argentina reported  an association 351 
between sun exposure and 25(OH)D (r=0.55, P<0.0001) in HD patients although the method for 352 
assessing exposure was not described (Del Valle et al., 2007). 353 
A limitation of this study is the cross-sectional design so that causal relationships and seasonal 354 
changes cannot be determined.  An Australian study investigating seasonal variation in 25(OH)D in 355 
Sydney found that levels peaked in Summer and Autumn (December to May) and were lowest in 356 
Winter and Spring (June to November) (Elder, 2007).  As our data was collected between August 357 
and early December it is possible that rates of deficiency/insufficiency were underestimated.   This 358 
study was restricted to a single hospital and only 37.2% of PD and 65% of HD patients agreed to 359 
participate, reducing statistical power and generalizability, although national data indicated no 360 
significant difference between participants and non-participants for age, gender, Kt/V and BMI.  361 
Non-participants and the eight participants that did not complete the questionnaire could differ from 362 
participants for factors such as compliance with recommendations and co-morbidities.  The 363 
differences in recruitment rates between PD and HD patients could also influence comparability of 364 
the data.  A likely reason for the lower response rate in the PD group was that completion of 365 
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measurements required extending the clinic visit whereas data from HD patients was collected 366 
during routine dialysis sessions.  It is possible that PD patients unable or unwilling to participate 367 
were more likely to have lower 25(OH)D and the difference between groups could be greater than 368 
that reported.   369 
The ability to identify associations between sun exposure and 25(OH)D may also have been limited 370 
by use of self-report data.  Participants may not have accurately recalled their sun exposure or the 371 
questionnaire may not have captured usual variation.  There is also evidence suggesting cutaneous 372 
cholecalciferol synthesis could be reduced in persons with lower GFR (Michaud et al., 2010).  The 373 
25(OH)D content of dialysate fluid was not measured and therefore could not be investigated to 374 
explain the lack of association between intake and 25(OH)D in our PD group.  Despite the 375 
limitations we were able to identify a very strong relationship between dietary plus supplemental 376 
intake and serum 25(OH)D and a trend for an association between dietary intake and 25(OH)D in 377 
HD patients.  This could be because vitamin D is confined to a relatively small range of foods and 378 
due to dietary restrictions CKD patients may be more aware than usual of their intakes.   379 
This study expands the limited data available on vitamin D intake and sunlight exposure of dialysis 380 
patients and extends the findings of previous research by identifying an association between vitamin 381 
D intake and 25(OH)D in HD but not PD patients.  This has implications relating to 382 
recommendations for restoration of 25(OH)D in PD patients as current guidelines do not 383 
differentiate between dialysis modes.  The study provides the first evidence on the occurrence of 384 
vitamin D deficiency in persons using dialysis at the latitude of Brisbane and supports previous 385 
findings of the higher rate in PD compared to HD patients and the presence of suboptimal 25(OH)D 386 
in persons living in a sunny climate. The lack of association between 25(OH)D and sunlight 387 
exposure in this group and the reports of suboptimal 25(OH)D in dialysis patients across a range of 388 
cultures and latitudes indicate the potential international relevance of these results.  Further 389 
longitudinal research including vitamin D intake, sunlight exposure, and serum and dialysate 390 
25(OH)D concentration is required to explore these findings.  Investigation of the relationship 391 
between 25(OH)D and health risks and benefits is also warranted.  Research could include larger 392 
observational studies conducted across a range of seasons and latitudes and intervention trials to 393 
assess the feasibility and efficacy of supplementation and advice in this group.   394 
 395 
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Table1 – Characteristics of the study population by dialysis mode1. 607 
Parameter 
Peritoneal Dialysis
(n=30) 
Haemodialysis 
(n=26) 
P 
Age (years)  56.87+16.16 63.58+15.09 0.1 
Gender 
Males 
Females 
13 (43.3%) 
17 (56.7%) 
21 (80.8%) 
5 (19.2%) 
0.004 
Ethnicity2 
Caucasian 
Asian 
PI/PNG 
ATSI 
South American 
African American
20 (66.7%) 
2 (6.7%) 
5 (16.7%) 
2 (6.7%) 
1 (3.3%) 
0 
18 (78.3%) 
2 (8.7%) 
0 (0) 
2 (8.7%) 
0 
1 (4.3%) 
0.3 
Duration of dialysis (months)  17.0 (1-70) 22.0 (2-166) 0.4 
Body mass index (kg/m2)3  26.3 (19.7-43.4) 26.4 (19.7-43.4) 0.9 
PG-SGA Score  4.5 (1-11) 3 (1-14) 0.09 
Kt/V  2.51+0.51 1.50+0.39 0.01 
Serum phosphorus (mmol/L)  1.64+0.42 1.85+0.62 0.2 
Serum potassium (mmol/L)  4.15+0.66 5.03+0.78  <0.001
Serum albumin (g/L)  34 (17-42) 36 (29-40) 0.1 
Serum urea nitrogen (mmol/L)  17.76+5.79 20.72+4.66  0.06 
Blood pressure (mmHg) 
systolic 
diastolic 
128.11+23.24 
77.57+14.36 
152.05+26.38 
69.38+19.12 
0.002 
0.09 
1Values expressed as mean+SD, number (percent) or median (range). Student unpaired t-test or 608 
Mann-Whitney U-Test used as appropriate.  609 
2Ethnicity not reported by 3 HD participants. 610 
3Weight/height unavailable for 4 HD participants. 611 
Abbreviations: PI/PNG, Pacific Islander/Papua New Guinea; ATSI, Aboriginal and/or Torres Strait 612 
Island 613 
 614 
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Table 2:  Comparison of 25-hydroxyvitamin D status, serum 25-hydroxyvitamin D, vitamin D 615 
intake and sun exposure between peritoneal dialysis and haemodialysis patients1,2 616 
  
Peritoneal Dialysis5 
(n=30) 
 
 
Haemodialysis5
(n=26) 
P 
Serum 25(OH)D (nmol/L)  33.10 (12.60-83) 53.7 (10.3-126) <0.001
Serum 25(OH)D status3 
Adequate 
Insufficient
Deficient 
7 
13 
10 
(23.3%) 
(43.3%) 
(33.3%) 
17 
8 
1 
(65.4%) 
(30.8%) 
(3.8%) 
0.002
Mean time outdoors 5am-7pm 
(min/d) 
 39 (0-366) 33 (0-454) 0.4 
Mean time outdoors 5am-7pm 
category: 
≥30 min/d 
< 30 min/d 
23 
15 
(60.5%) 
(39.5% 
10 
9 
(52.6%) 
(47.4%) 
0.6 
Dietary vitamin D intake (IU/d)  126.4 (14-300.4) 141.2 (56.8-458.4) 0.2 
Supplemental vitamin D intake 
(IU/d) 
 1000 (600-2000) 1000 (428-1000) 0.2 
Total vitamin D intake (IU/d4) 
 
 
140.8 (14-2041.6) 170 (56.8-1311.2) 0.8 
1Non supplement users excluded (n=7 PD, n=4 HD).  617 
2Values expressed as median (range) or number (percent). P calculated using Pearson’s Chi-Square 618 
test or Mann-Whitney U-Test, as appropriate.  619 
3Cut-points for 25(OH)D were: deficient, ≤ 25 nmol/L; insufficient, >25 to 50 nmol/L; adequate, ≥ 620 
50 nmol/L.  621 
4Total vitamin D intake calculated as the sum of dietary and supplemental intake. 622 
5Dietary vitamin D intake and sun exposure questions not available for 1 PD and 7 HD participants. 623 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; NRV, Nutrient Reference Values (National Health 624 
and Medical Research Council, 2006) 625 
 626 
 627 
 628 
 629 
 630 
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Table 3: Correlations between 25-hydroxyvitamin D and vitamin D intake or sun exposure in 631 
peritoneal dialysis and haemodialysis patients1 632 
 Peritoneal Dialysis3  
(n=29) 
Haemodialysis3  
(n=19) 
Dietary vitamin D intake -0.062 (0.7) 0.45 (0.06) 
Supplemental vitamin D intake 0.094 (0.6) 0.62 (0.001) 
Total vitamin D intake2 -0.056 (0.8) 0.84 (<0.001) 
Sun exposure average -0.030 (0.9) 0.53 (0.02) 
Sun exposure minimum week days 0.003 (0.9) 0.45 (0.05) 
Sun exposure maximum week days 0.22 (0.3) 0.504 (0.03) 
Sun exposure minimum weekends -0.23 (0.2) 0.42 (0.08) 
Sun exposure maximum weekends -0.008 (0.9) 0.49 (0.04) 
1P values (indicated in brackets) calculated using Spearman's rank-order correlation. 633 
2Total vitamin D intake calculated as the sum of dietary and supplemental intake.  634 
3Dietary vitamin D intake and sun exposure questions not available for 1 PD and 7 HD participants. 635 
 636 
  637 
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Table 4: Multiple regression predicting serum 25-hydroxyvitamin D from total vitamin D intake. 638 
Group Group 
B 
 (U. Coef.)
S.E. 
(B) 
95% CI for B 
ß 
(R. Coef.)
P 
Peritoneal dialysis Gender -11.63 7.79 [-27.70, 4.45] -.320 0.1 
 Age (years) -0.21 0.23 [-0.69, 0.27] -.186 0.4 
 
Average sun 
exposure (min/d) 
0.001 0.039 [-0.08, 0.08] .003 0.9 
 
Total vitamin D 
intake (IU/d) 
0.25 0.27 [-0.31, 0.802] .192 0.4 
Haemodialysis Gender -10.26 7.95 [-27.43, 6.92] -.122 0.2 
 Age (years) 0.039 0.22 [-0.44, 0.52] .019 0.9 
 
Average sun 
exposure (min/d) 
0.005 0.026 [-0.05, 0.06] .021 0.8 
 
Total vitamin D 
intake (IU/d) 
2.51 0.25 [1.97, 3.06] .919 <.001 
Abbreviations:  B (U. Coef.), Unstandardized coefficient); S.E. (B), standard error of B; 95% CI for 639 
B, 95% confidence interval for B; ß (R. Coef.), Standardized regression coefficient. 640 
 641 
 642 
 643 
 644 
